Addressing Cost-Related Medication Non-Adherence in Diabetes

Guest: Carel le Roux, MBChB, MSC, FRCP, FRCPath, PhD New findings from the SYNCHRONIZE-1 trial reveal that survodutide's impact extends beyond weight reduction, with a demonstrated decrease in liver fat and meaningful improvements across multiple markers of metabolic health in patients without type 2 diabetes. Dr. Carel le Roux joins us to share the efficacy and safety data and explore what these results could mean for the future of metabolic disease management. Dr. Le Roux is the Director of the Metabolic Medicine Group and a Professor of Chemical Pathology in the School of Medicine at University College Dublin, and he presented these findings at the 2026 American Diabetes Association Scientific Sessions.

Guest: Kimberly Narain, MD, MPH, PhD Cost-related medication nonadherence remains a significant but often hidden barrier to effective diabetes care, with out-of-pocket costs preventing patients from accessing essential therapies. Dr. Kimberly Narain joins us to explain why clinicians should look beyond insurance status alone and consider affordability challenges when developing strategies to improve diabetes outcomes. Dr. Narain is an Assistant Professor of Medicine at the David Geffen School of Medicine at UCLA, as well as the Director of Health Services and Health Optimization Research at the Iris Cantor UCLA Women's Health Center. She also spoke about this topic at the 2026 American Diabetes Association Scientific Sessions.

Guest: John W. Ostrominski, MD, MPH Despite advances in glycemic management, blood pressure control, lipid lowering, and disease-modifying therapies, patients with chronic kidney disease (CKD) and type 2 diabetes continue to face substantial residual cardiovascular risk. In this program, Dr. John Ostrominski reviews emerging evidence linking low-grade systemic inflammation to adverse cardiovascular outcomes in this high-risk population, highlighting findings from the FIDELITY pooled analysis of FIDELIO-DKD and FIGARO-DKD. Dr. Ostrominski is a fellow specializing in cardiovascular disease and obesity medicine at Brigham and Women's Hospital and Harvard Medical School. He spoke about this topic at the 2026 American Diabetes Association Scientific Sessions.

Host: Steve Jackson, PharmD Guest: Souptik Barua, PhD Guest: Emily Johnston, MPH, PhD Can older adults successfully engage with telehealth, wearable technology, and digital health tools to prevent type 2 diabetes? In this conversation with Dr. Steve Jackson, Dr. Emily Johnston and Dr. Souptik Barua discuss emerging insights on how these strategies could improve accessibility and engagement in a high-risk population. Dr. Johnston is a Research Assistant Professor in the Department of Medicine, and Dr. Barua is an Assistant Professor in the Division of Precision Medicine at the NYU Grossman School of Medicine. They presented these findings at the 2026 American Diabetes Association Scientific Sessions.

Guest: Javier Morales, MD, FACP, FACE For patients with obesity and type 2 diabetes (T2D), emerging incretin-based therapies that target multiple metabolic pathways are producing meaningful weight-loss outcomes. To learn more about these care strategies, tune in as Dr. Javier Morales shares key updates from the 2026 American Diabetes Association Scientific Sessions. Dr. Morales is an Associate Clinical Professor of Medicine at the Barbara and Donald Zucker School of Medicine at Hofstra University and Northwell Health.

Guest: Javier Morales, MD, FACP, FACE From proactive screening to once-weekly insulin, the treatment landscape for type 1 diabetes is evolving rapidly. Join Dr. Javier Morales to hear about current and emerging care strategies in these patients, a topic he also discussed at the 2026 American Diabetes Association Scientific Sessions. Dr. Morales is an Associate Clinical Professor of Medicine at the Barbara and Donald Zucker School of Medicine at Hofstra University and Northwell Health.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Ian de Boer, MD Since up to 40 percent of patients with diabetes develop diabetic kidney disease, it’s essential to know how to proactively diagnose and treat them using the latest therapeutic advances and strategies. Tune in to hear Dr. Mary Katherine Cheeley discuss diabetes management in patients with chronic kidney disease with Dr. Ian de Boer, Professor of Medicine in the Division of Nephrology and the Director of the Kidney Research Institute at the University of Washington in Seattle.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Ian de Boer, MD Since up to 40 percent of patients with diabetes develop diabetic kidney disease, it’s essential to know how to proactively diagnose and treat them using the latest therapeutic advances and strategies. Tune in to hear Dr. Mary Katherine Cheeley discuss diabetes management in patients with chronic kidney disease with Dr. Ian de Boer, Professor of Medicine in the Division of Nephrology and the Director of the Kidney Research Institute at the University of Washington in Seattle.

Guest: Elena Toschi, MD Approximately over the last decade, lifespans in the general population have increased, along with a rise in the prevalence of type 1 diabetes in older adult patients. Since each patient has a unique disease, the clinician should personalize and devise the best approach to diabetes management and glycemic targets, as well as manage comorbidities and complications. To learn more, join Dr. Elena Toschi, Director of the Young Adult Program at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School.

Guest: Elena Toschi, MD Approximately over the last decade, lifespans in the general population have increased, along with a rise in the prevalence of type 1 diabetes in older adult patients. Since each patient has a unique disease, the clinician should personalize and devise the best approach to diabetes management and glycemic targets, as well as manage comorbidities and complications. To learn more, join Dr. Elena Toschi, Director of the Young Adult Program at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School.